Bulky aggressive B-cell lymphoma: To radiate or not to radiate - That is the question

Journal of Clinical Oncology

Volumn 32, Issue 11, 2014, Pages 1097-1098

  Kahl, Brad S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISONE; RITUXIMAB; VINCRISTINE;

B CELL LYMPHOMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; EDITORIAL; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE QUALITY; HODGKIN DISEASE; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREMATURITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); FEMALE; MALE; NOTE;

FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE;

EID: 84901818293     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.1730     Document Type: Editorial

References (17)

1. Dores GM, Metayer C, Curtis RE, et al: Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population- based evaluation over 25 years. J Clin Oncol 20:3484-3494, 2002
2. Ng AK, Bernardo MV, Weller E, et al: Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors. Blood 100:1989-1996, 2002 (Pubitemid 35001228)
3. Hill DA, Gilbert E, Dores GM, et al: Breast cancer risk following radiotherapy for Hodgkin lymphoma: Modification by other risk factors. Blood 106:3358-3365, 2005 (Pubitemid 41609165)
4. Galper SL, Yu JB, Mauch PM, et al: Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 117:412-418, 2011
5. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al: Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21:3431-3439, 2003 (Pubitemid 46603515)
6. Ng AK, Bernardo MP, Weller E, et al: Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 20:2101-2108, 2002 (Pubitemid 34408801)
7. Miller TP, Dahlberg S, Cassady JR, et al: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339:21-26, 1998 (Pubitemid 28304493)
8. Horning SJ, Weller E, Kim K, et al: Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group Study 1484. J Clin Oncol 22:3032-3038, 2004 (Pubitemid 41103714)
9. Reyes F, Lepage E, Ganem G, et al: ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med, 352:1197-1205, 2005 (Pubitemid 40397261)
10. Bonnet C, Fillet G, Mounier N, et al: CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 25:787-792, 2007 (Pubitemid 350002878)
11. Persky DO, Unger JM, Spier CM, et al: Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 26:2258-2263, 2008
12. Phan J, Mazloom A, Medeiros LJ, et al: Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 28:4170-4176, 2010
13. Held G, Murawski N, Ziepert M, et al: Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol 32:1112-1118, 2014
14. Pfreundschuh M, Schubert J, Ziepert M, et al: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116, 2008
15. Juweid ME, Wiseman GA, Vose JM, et al: Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and flouorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23:4652-4661, 2005 (Pubitemid 46224067)
16. Sehn LH, Savage KJ, Hoskins P: Treatment of limited-stage DLBCL can be effectively tailored using a PET-based approach. Ann Oncol 22, 2011 (suppl 4; abstr 28)
17. Swerdlow AJ, Barber JA, Hudson GV, et al: Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment. J Clin Oncol 18:498-509, 2000 (Pubitemid 30078531)